Cipla Brasil Importadora E Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: Cipla Brasil Importadora E Pharmaceutical Import Records from India — 2 Products, $404.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cipla Brasil Importadora E — Pharmaceutical Importer Profile (2026) | 2 Products, $404.8K Trade | TransData Nexus

Cipla Brasil Importadora E

Pharmaceutical Importer · Brazil · Advanced Oncology Focus · $404.8K Total Trade · DGFT Verified

Cipla Brasil Importadora E is a pharmaceutical importer based in Brazil with a total trade value of $404.8K across 2 products in 2 therapeutic categories. Based on 11 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cipla Brasil Importadora E sources from 5 verified Indian suppliers, with Cipla Limited accounting for 95.5% of imports.

Cipla Brasil Importadora E — Import Portfolio & Supplier Network

Cipla Brasil Importadora E import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cipla Brasil Importadora E?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$693.7K	99	95.5%
Orbicular Pharmaceutical Technologies Private Limited	$21.6K	18	3.0%
Orbicular Pharmaceutical Technologies Private Limi	$7.9K	14	1.1%

What Formulations Does Cipla Brasil Importadora E Import?

Formulation	Value	Ships
Tykiticip 250 MG tablets commercial gefitinib 250 MG 442 packs x 3x10's=13260	$138.5K	3
Tykiticip 250 MG tablets commercial (gefitinib 250 MG) (442packs x 3x10's=13260nos)	$50.0K	1
Icatibant injection 30MG/3ML (1x3ml) (312pack)	$50.0K	1
Icatibant injection 30MG/3ML(1x3ml) (288 packs)	$50.0K	1
Icatibant injection 30MG/3ML (1x3ml) (288 Pack)	$50.0K	1
Icatibant injection 30MG/3ML (1x3ml)(285 Pack)	$50.0K	1
Tykiticip 250 MG tablets commercial (gefitinib 250 MG)(1380 packs x3x10s=41400 nos)	$50.0K	1
Tykiticip 250 MG tablets commercial(gefitinib 250 MG) (1820 packs x 3x10s=54600 nos)	$50.0K	1
Tykiticip 250MG tablets (gefitinib 250MG	$45.9K	1
Tykiticip 250 MG tablets commercial (gefitinib 250 MG)(3 x 10's x 480 =14400 nos)	$29.8K	1
Tykiticip 250 MG tablets commercial(gefitinib 250 MG)(442 packs x3x10s= 13260 nos	$28.0K	1
Tykiticip 250 MG tablets commercial (gefitinib 250 MG) (442 packx3x10's=13260 nos	$28.0K	1
Tykiticip 250 MG tablets commercial (gefitinib 250 MG) (442packx3x10's=13260num)	$27.9K	1
Amphotericin b liposomal powder for solution for infusion 50 MG	$25.6K	2
Parathyroid hormone (1-34) human acetate(teriparatide)	$6.0K	1

Cipla Brasil Importadora E imports 102 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gefitinib	Advanced Oncology	$400.0K	8	5.9%	2
2	Liraglutide	Diabetes & Endocrine	$4.8K	3	0.1%	11

Cipla Brasil Importadora E imports 2 pharmaceutical products across 2 categories into Brazil totaling $404.8K.

Cipla Brasil Importadora E — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cipla Brasil Importadora e Distribuidora de Medicamentos Ltda., commonly known as Cipla Brasil, is a Brazilian pharmaceutical importer and distributor headquartered in Vargem Grande Paulista, São Paulo. Established on June 10, 2013, the company operates as a limited liability entity with a capital investment of R$ 20,000,000. (inteligen.com.br) Cipla Brasil specializes in the wholesale distribution of human-use pharmaceuticals, including medications, medical instruments, and laboratory materials. (inteligen.com.br)

As a subsidiary of Cipla Limited, an Indian multinational pharmaceutical company founded in 1935, Cipla Brasil plays a pivotal role in facilitating the availability of Cipla's diverse product portfolio within the Brazilian market. Cipla Limited is renowned for its extensive range of pharmaceutical products, encompassing treatments for respiratory diseases, cardiovascular conditions, arthritis, diabetes, depression, and pediatric care. Cipla Brasil's operations are integral to Cipla Limited's global strategy, ensuring the distribution of high-quality, affordable medicines to meet the healthcare needs of Brazilian patients.

2Distribution Network

Cipla Brasil's distribution network is strategically located in Vargem Grande Paulista, São Paulo, serving as the central hub for its operations. The company's logistics capabilities are designed to efficiently manage the import and distribution of pharmaceutical products across Brazil. While specific details regarding additional warehouse locations and geographic coverage are not publicly disclosed, Cipla Brasil's central location in São Paulo positions it advantageously to serve both domestic and international markets. This strategic positioning enables the company to effectively distribute a wide range of pharmaceutical products throughout Brazil and potentially to neighboring countries.

3Industry Role

Cipla Brasil Importadora e Distribuidora de Medicamentos Ltda. functions primarily as a pharmaceutical importer and distributor within Brazil's healthcare supply chain. By sourcing finished pharmaceutical formulations from Cipla Limited in India, the company ensures the availability of a diverse array of medications to meet the therapeutic needs of Brazilian patients. Cipla Brasil's role is crucial in bridging the gap between international pharmaceutical manufacturing and the Brazilian market, facilitating access to essential medicines and contributing to the overall efficiency of the country's pharmaceutical distribution network.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cipla Brasil Importadora E

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cipla Brasil's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from Cipla Limited in India. Between 2022 and 2026, the company imported a total of $405,000 USD worth of pharmaceutical products from India, comprising 11 shipments. The top five products imported during this period include Gefitinib ($400,000 USD, 5.9% share) and Liraglutide ($5,000 USD, 0.1% share). This concentration indicates a strategic partnership with Cipla Limited, leveraging their extensive product portfolio to meet the demands of the Brazilian market.

The reliance on a single supplier, Cipla Limited, may present certain risks, such as potential supply chain disruptions or dependency on the supplier's production capabilities. However, this concentrated sourcing approach also suggests a stable and well-established relationship between Cipla Brasil and Cipla Limited, likely characterized by favorable terms and consistent product quality. The substantial import value and frequency of shipments underscore the importance of this partnership in Cipla Brasil's operational strategy.

2Supply Chain Resilience

Cipla Brasil's supply chain resilience is closely tied to its exclusive sourcing from Cipla Limited in India. This singular supplier relationship may expose Cipla Brasil to risks associated with supply chain disruptions, such as production delays, logistical challenges, or geopolitical factors affecting trade between India and Brazil. The company's import data indicates a consistent pattern of shipments, suggesting a stable supply chain; however, the lack of publicly available information on backup suppliers or alternative sourcing strategies limits the assessment of Cipla Brasil's preparedness for potential supply chain disruptions.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the primary regulatory authority overseeing the pharmaceutical sector is the National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA). ANVISA is responsible for regulating and supervising the production, importation, distribution, and commercialization of pharmaceutical products to ensure public health safety. Key legislation governing pharmaceutical imports includes the Brazilian Health Regulatory Agency's regulations and the National Health Surveillance Agency's guidelines, which outline the requirements for marketing authorization, quality control, and post-market surveillance.

For Indian pharmaceutical companies aiming to export to Brazil, obtaining marketing authorization from ANVISA is mandatory. The authorization process involves submitting comprehensive documentation, including product dossiers, clinical trial data, and evidence of Good Manufacturing Practice (GMP) compliance. ANVISA evaluates these submissions to ensure that imported pharmaceutical products meet the necessary safety, efficacy, and quality standards before granting approval for commercialization in Brazil.

2Import Licensing & GMP

Import licensing in Brazil is governed by ANVISA, which requires all pharmaceutical imports to be accompanied by appropriate licenses and certifications. Indian pharmaceutical exporters must ensure that their products are registered with ANVISA and that they possess valid import licenses before entering the Brazilian market. Additionally, ANVISA mandates that imported pharmaceutical products comply with GMP standards recognized by international bodies, such as the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications attest to the manufacturing quality and safety of the products, which is crucial for obtaining import approval.

Cipla Brasil Importadora E — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cipla Brasil's product strategy focuses on importing pharmaceutical formulations that address critical therapeutic areas, notably advanced oncology and diabetes. The company's import data indicates a predominant emphasis on advanced oncology products, with Gefitinib accounting for $400,000 USD of the total import value, representing a 5.9% share. This focus aligns with the growing demand for cancer treatments in Brazil, where oncology remains a significant public health concern.

The inclusion of Liraglutide, a medication used in the management of diabetes, reflects Cipla Brasil's commitment to addressing the rising prevalence of diabetes in Brazil. By importing these specific therapeutic products, Cipla Brasil aims to meet the critical healthcare needs of the Brazilian population, ensuring access to effective treatments for complex and chronic conditions.

2Sourcing Profile

Cipla Brasil's sourcing strategy is centered on importing generic pharmaceutical formulations from Cipla Limited in India.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Cipla Brasil Importadora E

What products does Cipla Brasil Importadora E import from India?

Cipla Brasil Importadora E imports 2 pharmaceutical products across 2 categories. Top imports: Gefitinib ($400.0K), Liraglutide ($4.8K).

Who supplies pharmaceuticals to Cipla Brasil Importadora E from India?

Cipla Brasil Importadora E sources from 5 verified Indian suppliers. The primary supplier is Cipla Limited (95.5% of imports, $693.7K).

What is Cipla Brasil Importadora E's total pharmaceutical import value?

Cipla Brasil Importadora E's total pharmaceutical import value from India is $404.8K, based on 11 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cipla Brasil Importadora E focus on?

Cipla Brasil Importadora E imports across 2 categories. The largest: Advanced Oncology (98.8%), Diabetes & Endocrine (1.2%).

Get Full Cipla Brasil Importadora E Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.